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ABSTRACT
Objective Clinical data comparing diagnostic strategies 
in the management of Helicobacter pylori- associated 
diseases are limited. Invasive and noninvasive diagnostic 
tests for detecting H. pylori infection are used in the 
clinical care of patients with dyspeptic symptoms. 
Modelling studies might help to identify the most cost- 
effective strategies. The objective of the study is to assess 
the cost- effectiveness of a ‘test- and- treat’ strategy with 
the urea breath test (UBT) compared with other strategies, 
in managing patients with H. pylori- associated dyspepsia 
and preventing peptic ulcer in the UK.
Design Cost- effectiveness models compared four 
strategies: ‘test- and- treat’ with either UBT or faecal 
antigen test (FAT), ‘endoscopy- based strategy’ and 
‘symptomatic treatment’. A probabilistic cost- effectiveness 
analysis was performed using a simulation model in order 
to identify probabilities and costs associated with relief 
of dyspepsia symptoms (over a 4- week time horizon) 
and with prevention of peptic ulcers (over a 10- year 
time horizon). Clinical and cost inputs to the model were 
derived from routine medical practice in the UK.
Results For relief of dyspepsia symptoms, ‘test- and- 
treat’ strategies with either UBT (€526/success) and 
FAT (€518/success) were the most cost- effective 
strategies compared with ‘endoscopy- based strategy’ 
(€1317/success) and ‘symptomatic treatment’ (€1 029/
success). For the prevention of peptic ulcers, ‘test- and- 
treat’ strategies with either UBT (€208/ulcer avoided/
year) or FAT (€191/ulcer avoided/year) were the most 
cost- effective strategies compared with ‘endoscopy- 
based strategy’ (€717/ulcer avoided/year) and 
‘symptomatic treatment’ (€651/ulcer avoided/year) (1 
EUR=0,871487 GBP at the time of the study).
Conclusion ‘Test- and- treat’ strategies with either UBT 
or FAT are the most cost- effective medical approaches for 
the management of H. pylori- associated dyspepsia and 
the prevention of peptic ulcer in the UK. A ‘test- and- treat’ 
strategy with UBT has comparable cost- effectiveness 
outcomes to the current standard of care using FAT in the 
UK.
INTRODUCTION
Between 20% to 30% of people in Western 
Europe are infected with Helicobacter pylori 
(H. pylori)1 and these infections play a caus-
ative role in the development of dyspepsia, 
peptic ulcers, gastric adenocarcinoma and 
gastric mucosa- associated lymphoid tissue 
lymphoma.2–7 However, in most cases, H. 
pylori infections can be successfully elimi-
nated with appropriate antibiotic treatment.8 
For this reason, timely detection of H. pylori 
infections in individuals presenting with 
symptoms of dyspepsia is an important public 
Summary
What is already known about this subject?
 ► Cost- effectiveness studies comparing strategies 
used for the management of Helicobacter pylori- 
associated diseases are limited.
 ► Timely detection of H. pylori infections in individuals 
presenting with symptoms of dyspepsia is an im-
portant public health issue in order to prevent the 
development of serious long- term complications 
such as gastric cancer.
 ► In the UK, faecal antigen test (FAT) is the most 
widely used noninvasive screening procedure for H. 
pylori, but no recent data about the relative cost- 
effectiveness of this strategy are available.
What are the new findings?
 ► ‘Test- and- treat’ strategies with either UBT or FAT 
are the most cost- effective medical approaches for 
the management of H. pylori- associated dyspepsia 
and the prevention of peptic ulcer in the UK.
 ► ‘Test- and- treat’ strategy with UBT has comparable 
cost- effectiveness outcomes to the strategy using 
FAT.
How might it impact on clinical practice in the 
foreseeable future?
 ► Provide decision- makers with comparative data on 
the cost- effectiveness of noninvasive tests for test-
ing and retesting for H. pylori infection.
 ► Confirm that noninvasive tests such as UBT repre-
sent cost- effective and practical options for use in 
routine clinical practice in the UK.
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health issue in order to prevent the development of 
serious long- term complications.9–11 Moreover, in spite of 
the initial cost, screening for H. pylori has been shown to 
generate significant reductions in total dyspepsia- related 
healthcare costs over the long term.12 Such screening 
programmes may also be cost- effective for the prevention 
of gastric carcinoma.13 14
Historically, H. pylori infections were typically diagnosed 
by analysis of biopsy samples taken from the stomach 
during endoscopy. However, this is an invasive procedure 
requiring hospital attendance and is resource consuming 
in terms of endoscopists’ time and laboratory testing. 
For this reason, alternative diagnostic methods that are 
simpler to use and can be performed in the community 
are of interest. In this respect, two types of noninvasive 
tests have been developed. The faecal antigen test (FAT) 
involves collecting a faecal sample that is sent for assay 
of H. pylori- specific antigens using enzyme immunoassay 
or immunochromatography.15 16 The urea breath test 
(UBT) involves ingestion of [13C]-urea, which is broken 
down in the stomach by urease produced by H. pylori to 
ammonia and carbon dioxide. The presence of [13C]-
CO2 in exhaled air is then detected by mass spectroscopy 
or infrared technologies.
Individual patient meta- analysis has demonstrated that 
test- and- treat strategies using FAT or UBT provide compa-
rable effectiveness at relieving symptoms of dyspepsia 
as first- line endoscopy, but at a greatly reduced cost.17 
Similar, although less robust, conclusions may be drawn 
for noninvasive test- and- treat strategies compared with 
empirical symptomatic treatment.18 19 For this reason, 
noninvasive H. pylori screening is now recommended in 
young patients with dyspepsia who do not have alarm 
symptoms.8 19 In England and Wales, practice guidelines 
produced by the National Institute for Health and Clin-
ical Excellence (NICE) recommend that clinicians offer 
patients with dyspepsia under 55 years and who do not 
have alarm symptoms noninvasive H. pylori testing using 
UBT, FAT or laboratory- based serology where its perfor-
mance has been locally validated.20
We have recently performed a cost- effectiveness model-
ling study comparing a ‘test- and- treat’ strategy with UBT, 
‘test- and- treat’ using endoscopy and empirical symptom-
atic treatment in the Spanish treatment setting.21 This 
study demonstrated that the UBT ‘test- and- treat’ strategy 
was the most cost- effective medical approach for manage-
ment of dyspepsia and for the prevention of peptic ulcers 
and gastric cancer. However, this modelling study did not 
compare UBT with FAT, which is not widely used in Spain. 
In contrast, in the UK, FAT is the most widely used nonin-
vasive screening procedure for H. pylori,22 but no recent 
data about the relative cost- effectiveness of these different 
strategies are available. For these reasons, we undertook 
a second modelling study based on practices and costs in 
the UK. The objective of this study was to compare the 
cost- effectiveness of four different management strategies 
(UBT, FAT, endoscopy and empirical symptomatic treat-
ment) in the context of the British healthcare system.
MATERIALS AND METHODS
Study design
This medicoeconomic modelling study estimated the 
cost- effectiveness of the ‘test- and treat’ strategy using 
UBT in the diagnosis of H. pylori infection and in the 
subsequent prevention of H. pylori- related complications. 
The ‘test- and treat’ strategy using UBT for primary detec-
tion of H. pylori was compared with three other diag-
nostic strategies, namely, ‘test- and treat’ using FAT, an 
‘endoscopy- based strategy’ and a ‘strategy starting directly 
with empirical symptomatic treatment’. Two therapeutic 
outcomes were evaluated, relief of symptoms of dyspepsia 
and prevention of peptic ulcers. Values and costs were 
estimated from a decision tree model simulating the four 
strategies. The management pathways modelled corre-
spond to those used in routine clinical practice in the 
UK, and transition probabilities were based on British 
data whenever available. Due to uncertainty associated 
with the estimates of several model inputs, probabilistic 
simulations were used to derive estimates of costs and 
outcomes. The analysis was performed from a public 
health insurance perspective, taking into account direct 
medical costs only. No cost discounting was applied.
Description of the model
The decision tree model used in the study consisted of a 
succession of decision nodes identifying decisions to test 
for H. pylori, to undertake endoscopy, to initiate symptom-
atic treatment or antibiotic treatment for H. pylori erad-
ication and to evaluate effectiveness. A corresponding 
set of event nodes identify the possible outcomes of 
these decisions. Each branch of the decision tree ends 
in a terminal node defined by the therapeutic outcome 
(success or failure). Independent decision trees were 
constructed for each of the four management strategies 
evaluated. These decision tree models used in the study 
are illustrated schematically in online supplemental 
material.
UBT and FAT strategies
These two strategies follow an identical management 
pathway. The first step is testing for H. pylori with one 
of the two methods. If the pathogen is detected, first- 
line antibiotic therapy with clarithromycin- based triple 
therapy is initiated to eradicate it (according to the 
reference guide published by Public Health England).23 
If a switch to other first- line therapies would become 
necessary (ie, clarithromycin resistance >15%), costs of 
therapy will remain similar. At the end of the prescribed 
treatment course, the patient is retested by UBT or FAT. 
In case of persistence of the infection, a second- line erad-
ication treatment is initiated and the patient then tested 
again. Therapeutic outcomes are modelled after first- 
line therapy in the case of successful eradication or after 
second- line therapy regardless of whether eradication 
had been achieved.
In the case of a negative H. pylori test, symptomatic treat-
ment, including mainly a proton pump inhibitor (PPI), 
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is initiated for 4 weeks, and therapeutic outcome is eval-
uated at the end of this period. If symptoms have been 
relieved, the treatment is considered successful. If not, 
the patient undergoes endoscopy to identify any poten-
tial lesion (peptic ulcer or other macroscopic pathology).
Endoscopy-based strategy
In this strategy, the first step is to perform an endoscopy 
to detect any lesion and to take biopsies for H. pylori assay. 
If the assay result is negative, a 4- week symptomatic treat-
ment is initiated after which outcome (symptom relief) 
is evaluated. If the result is positive, the patient under-
goes first- line, and, if a retest is again positive, second- 
line, antibiotic treatment to eradicate the pathogen. As 
in the UBT and FAT strategies, therapeutic outcomes are 
modelled after first- line therapy in the case of successful 
eradication or after second- line therapy regardless of 
whether eradication had been achieved.
Empirical symptomatic treatment strategy
In this strategy, the first step is to start empirical symptom-
atic treatment with a PPI for 4 weeks. If symptoms have 
been relieved, the treatment is considered successful. If 
not, the patient undergoes endoscopy and follows the 
endoscopy strategy described above.
End states
For each management strategy, two end states were 
modelled. The first was the relief of dyspepsia symp-
toms at 4 weeks after initiation of symptomatic treatment 
(either following a negative H. pylori test in the two ‘test 
and treat’ and the ‘endoscopy- based’ strategies or during 
the first stage of the model in the ‘treat- and- test’ symp-
tomatic treatment strategy). The second endpoint was 
prevention of occurrence (or recurrence) of a peptic 
ulcer over 10 years following a negative H. pylori test. Both 
end states were considered as binary variables (symptom 
relief vs no symptom relief and ulcer prevented vs ulcer 
not prevented). A payoff of 1 was assigned if the treat-




The analysis population modelled corresponded to 
patients consulting a gastroenterologist for symptoms of 
dyspepsia.
Transition probabilities
Transition probabilities for the different chance nodes of 
the decision tree are listed in table 1.
Cost inputs
For certain items, a fixed cost was applied when this 
was known. For others, a cost range was applied, corre-
sponding to the different treatment options available 
(eg, for antibiotic treatment for elimination of H. pylori), 
differences in laboratory costs for test assays or to expert 
opinion when the exact cost was unknown (eg, for the 
management of peptic ulcer). All costs used in the model 
are presented in euros (1 EUR=0,871487 GBP) and are 
listed in table 2.
For the UBT and FAT, costs include kit acquisition 
and test analysis. For endoscopy, two possible costs were 
applied. In the case when endoscopy revealed no suspect 
lesions, the cost applied was the procedure cost of endos-
copy along with a rapid urease test. If suspect lesions 
were identified and biopsy samples were taken, the cost 
Table 1 Model inputs: transition probabilities
Event Probability Range Source
H. pylori positivity rate by UBT 0.16 Allison et al22
H. pylori positivity rate by FAT 0.13 Allison et al22
Lesion frequency during endoscopy 0.05 Ching et al30
H. pylori positivity rate by endoscopy (no lesion) 0.12 Moore31
H. pylori positivity rate by endoscopy (with lesion) 0.51 Zullo et al32
H. pylori eradication rate after first line antibiotic treatment 0.84 Nayar33
H. pylori eradication rate after second line antibiotic 
treatment
0.78 Lin and Hsu34
Dyspepsia relief after 4 week symptomatic treatment 0.3–0.4 Rabeneck et al35
Dyspepsia relief after 48 week symptomatic treatment (H. 
pylori negative)
0.12 Pinto- Sanchez et al36
Dyspepsia relief after H. pylori eradication 0.4–0.73 Du et al37
Dyspepsia relief after H. pylori eradication failure 0.32–0.54 Ford et al17 and Heaney et al38
Peptic ulcer after 4 week symptomatic treatment 0.05–0.25 Rabeneck et al35 and Färkkilä et al39
Peptic ulcer after H. pylori eradication 0.07 Gisbert et al40
Peptic ulcer after H. pylori eradication failure 0.55 Gisbert et al40
Lesions detected during endoscopy are generally related to gastric or duodenal lesions such as ulceration or precancerous lesions.
FAT, faecal antigen test; UBT, urea breath test.
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of histological testing for H. pylori was also included. It 
was assumed that five biopsy samples would be analysed 
by histology and one rapid urease test. These procedures 
were costed according to NHS National tariffs. If an ulcer 
was detected by endoscopy, then the cost of management 
was included.
Acquisition costs for symptomatic treatment of 
dyspepsia and for antibiotic treatment for elimination of 
H. pylori were taken from the recommended retail price 
listed in the NHS National tariff.
Model outputs
Values
For each treatment strategy, the expected value of each 
outcome of interest was computed as the product of 
the transition probabilities at each node of the rele-
vant branch of the tree. Monte Carlo simulations were 
performed with 10 000 iterations, each using a randomly 
selected transition probability within the prespecified 
range. Expected values are presented as the mean and 
SD of the results of the individual Monte Carlo iterations.
Costs
For each treatment strategy, the total cost of each outcome 
of interest was computed according to the probabilities 
at each node of the tree. Monte Carlo simulations were 
performed with 10 000 iterations, each using a randomly 
selected value within the prespecified cost range. Total 
costs are presented as the mean and SD of the results of 
the individual Monte Carlo iterations.
Cost-effectiveness
Cost- effectiveness ratios were calculated for each strategy 
and each outcome. In the case of dyspepsia relief, costs 
of the symptomatic treatment course were divided by the 
value (probability of symptom relief by the treatment 
course). In the case of ulcer prevention, the cost over 10 
years was divided by the value (1—probability of devel-
oping an ulcer) and divided by 10 to generate an annual 
cost/outcome. Monte Carlo simulations were performed 
with 10 000 iterations, each using randomly selected 
values for values and costs within the ranges used in the 
previous step. These ratios are presented as the mean and 
SD of the results of the individual Monte Carlo iterations.
RESULTS
Value outcomes
For dyspepsia relief, the expected value of the treatment 
strategy ranged from 0.38 for endoscopy to 0.58 for the 
FAT (table 3). For prevention of peptic ulcer occur-
rence/recurrence, the expected value of the treatment 
strategy ranged from 0.10 for symptomatic treatment to 
0.15 for the UBT and for the FAT (table 3).
Cost outcomes
For dyspepsia relief, the total cost of the treatment strategy 
ranged from €298 for the FAT to €497 for endoscopy 
(table 3). For prevention of peptic ulcer occurrence/
recurrence, the total 10- year cost of the treatment strategy 
Table 3 Model outputs: costs and values according to management strategy
Dyspepsia relief Peptic ulcer prevention
Cost/treatment Value Cost/year Value
Urea breath test €302±228 0.57±0.03 €174±305 0.85±0.05
Faecal antigen test €298±227 0.58±0.02 €159±306 0.85±0.05
Endoscopy €497±14 0.38±0.03 €610±306 0.84±0.05
Symptomatic treatment €479±342 0.47±0.02 €584±423 0.90±0.02
Values are presented as mean values±SD.
Table 2 Model inputs: costs
Item Fixed cost (€) Cost range (€) Source
Endoscopy with urease test 474 NHS National Tariff
Endoscopy with biopsy 514 NHS National Tariff
UBT kit and assay 22–36.4 BNF
FAT kit and assay 16.7 13.8–21.8 Expert opinion
Follow- up test after eradication 22–36.4 BNF
Symptomatic treatment 19.2–27.1 BNF
Antibiotic treatment (first line) 19.1–26.9 BNF
Antibiotic treatment (second line) 19.1–34.7 BNF
Management of peptic ulcer 575–1150 Expert opinion
UBT, urea breath test; FAT, faecal antigen test; BNF, British National Formulary.
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ranged from €1595 for the FAT to €6105 for endoscopy 
(table 3).
Cost-effectiveness
Costs and values for each treatment strategy are displayed 
on a cost- effectiveness plane in figure 1. For both outcomes 
(dyspepsia relief and ulcer prevention), the FAT and the 
UBT dominated endoscopy and symptomatic treatment, 
being more effective and cheaper. The cost- effectiveness 
ratio for FAT and for UBT was very similar, €518±397 per 
event and €526±400 per event, respectively, for dyspepsia 
relief and €191±371 per event and €208±368 per event, 
respectively, for ulcer prevention.
DISCUSSION
This modelling study indicates that a test- and- treat 
strategy in patients with dyspepsia using FAT or UBT for 
H. pylori offers a probability of relief of dyspepsia or of 
ulcer prevention at least as high as that offered by endos-
copy or by an empirical symptomatic treatment. However, 
the cost of the strategy per patient successfully treated is 
over three times lower for dyspepsia relief and over two 
times lower for ulcer prevention with the noninvasive 
strategies compared with endoscopy or empirical symp-
tomatic treatment. Compared with FAT, UBT shows a 
very similar cost- effectiveness profile. These findings are 
consistent with current recommendations from NICE,20 
the Scottish Intercollegiate Guidelines Network24 and 
other international professional bodies,8 which recom-
mend a noninvasive test- and- treat strategy for diagnosis 
of H. pylori infections and management of H. pylori- 
related disease.
The UK is considered a low- prevalence country for H. 
pylori,25 and the proportion of patients with dyspepsia 
who are tested positive for this organism is likely to be 
around 15%.23 It should be noted that the actual prev-
alence of H. pylori infection in dyspeptic patients in the 
UK has not recently been comprehensively assessed and 
that any estimate higher than 15% in H. pylori prevalence 
would benefit test- and- treat strategy cost- effectiveness 
outcomes. In addition, diagnostic tests need to have high 
performance rates and to be cheap, in order to be cost 
effective. The UBT fulfils both these conditions, with 
sensitivity, specificity, positive predictive value and nega-
tive predictive value all being >95%,26 comparable to the 
performance of the FAT.16
In spite of the fact that UBT is the most accurate 
noninvasive test for H. pylori27 28 and is recommended 
by NICE,20 it remains relatively underused compared 
with FAT in the UK. A survey of all accredited microbi-
ology laboratories in England, conducted in 2015, found 
that >90% of laboratories proposed FAT as the first- line 
diagnostic test compared with <5% who proposed the 
UBT.22 Since UBT, unlike FAT, requires prescription of 
the labelled reagent, the authors of this study speculated 
that physicians were not encouraged to prescribe by their 
local funding body.
Compared with our previous cost- effectiveness model-
ling study in the Spanish setting,21 and despite the differ-
ences between healthcare systems and the prevalence of 
H. pylori, the results were similar. In both Spanish and 
British settings, the cost per treatment success was higher 
for the endoscopy and empirical treatment strategies 
than for the UBT strategy.
The currently available noninvasive strategies for H. 
pylori assessment do not provide information about anti-
biotic susceptibility. However, real- time PCR tests have 
been developed that permit assessment of clarithro-
mycin susceptibility using faecal samples.29 These may be 
helpful in the future, but at present are not readily avail-
able in the UK and elsewhere. If these tests are used for 
additional characterisation of H. pylori- positive patients 
in the future, this would potentially increase the cost 
of a stool- based testing strategy but will comply with the 
demands for a proper antibiotic stewardship in manage-
ment of H.pylori infection.
The study has a number of limitations. In particular, 
the transition probabilities and certain costs used in the 
model are not known with precision for the UK context, 
and a range of values has been tested for most variables 
using a probabilistic approach. In consequence, the 
model outputs (costs and values) are also limited in their 
precision. Second, the model assumes that all patients 
offered FAT, UBT or endoscopy will actually undertake 
them. Any differences in test acceptability and patient 
uptake will not be reflected in the model.
In conclusion, this health economic modelling study 
predicts that ‘test- and- treat’ strategies with either UBT or 
FAT are the most cost- effective medical approaches for 
the management of H. pylori- associated dyspepsia and the 
Figure 1 Cost- effectiveness ratio for each strategy. Filled 
symbols: dyspepsia relief; open symbols: prevention of 
peptic ulcer occurrence/recurrence. Endo, endoscopy (♦,◊); 
FAT, faecal antigen test (■,□); ST, symptomatic treatment 
(▲,△); UBT, urea breath test (●,○).
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prevention of peptic ulcer in the UK. The ‘test- and- treat’ 
strategy with UBT has comparable cost- effectiveness 
outcomes to the current standard of care using FAT in 
the UK.
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